Abstract 187P
Background
The tumour microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) is a complex ecosystem that facilitates ovarian cancer progression. However, further investigation is required to elucidate the precise role of the TME.
Methods
In this study, single-cell RNA sequencing was employed to profile the TME in freshly collected HGSOC samples, comprising two normal ovarian cortex samples and six HGSOC samples.
Results
A total of 55,430 single cells obtained from ovarian and HGSOC tissues were subjected to single-cell RNA sequencing (scRNA-seq). The cells were divided into seven clusters, comprising B cells, T and NK cells, myeloid cells, endothelial cells, fibroblasts, epithelial cells and mast cells. The proportion of B cells, myeloid cells, mast cells and T & NK cells was greater in HGSOC samples than in ovary cortex samples, whereas the percentage of epithelial cells was lower in the former. The analysis of intercommunication of epithelial cells with other cell clusters indicated that the interactions between epithelial cells and fibroblast cells, T & NK cells, B cells as well as myeloid cells were enhanced in in HGSOC samples comparing ovary cortex samples. Additionally, we identified a subcluster of epithelial cells (E7) and a subcluster of fibroblast cells (F7) that were implicated in tumour formation. Finally, we examined the intercommunication between E7 and F7. One of the most significant ligand-receptor signals identified was THBS2-CD74.
Conclusions
The results clearly demonstrated an increase in immune cell percentage in ovarian cancer tissue. Malignant cell clusters, designated as fibroblast cells F7 and epithelial cells E7, were also identified. Among the interactions between F7 and E7, the THBS2-CD74 signal emerged as a crucial factor in the tumourigenesis of HGSOC.
Legal entity responsible for the study
Beijing Obstetrics and Gynecology, Capital Medical University.
Funding
National Natural Science Foundation of China (No. 82373397), the Capital’s Funds for Health Improvement and Research (No. 2022-2-2116), Beijing Municipal Administration of Hospitals Incubating Program (No.PX2022057) and Beijing Obstetrics and Gynecology Hospital, Capital Medical University (No. FCYY201915).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract